This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: AstraZeneca Acquires Amplimmune for $500M

NEW YORK ( TheStreet) -- London biopharmaceutical conglomerate AstraZaneca (AAPL) said Monday it agreed to acquire venture capital-backed cancer drug research company Amplimmune for up to $500 million.

Amplimmune becomes the second cancer drug developer to be acquired in less than 24 hours. On Sunday Amgen (AMGN), agreed to buy Onyx Pharmaceuticals (ONYX) for $10.4 billion. AstraZeneca had been mentioned as a possible bidder for Onyx after the target received a $10 billion unsolicited bid from Amgen in June and put itself on the auction block.

Under financial terms of the Amplimmune acquisition, AstraZeneca will pay $225 million upfront and up to another $275 million in earnouts if the target hits certain milestones.

Amplimmune's main AMP-514 cancer therapy drug candidate is currently in pre-clinical stages and the Gaithersburg, Md.-based company, founded in 2007, expects to take the drug candidate to clinical trials by year's end.

InterWest Partners and Wellcome Trust are Amplimmune backers. The two firms collectively invested about $20 million in Amplimmune in 2007.

"Both companies are passionate about developing new cancer therapies for patients and are excited about the potential of immunotherapies," said Amplimmune CEO Michael Richman in a statement.

AstraZeneca will make the acquisition through its MedImmune subsidiary.

The Amplimmune deal is the latest in what has been an active M&A year for AstraZeneca as it looks to restock its drug pipeline that has been hurt by upcoming expiring patents, including one for its Nexium heartburn medicine, which is set to expire in mid 2014.

In June, AstraZeneca acquired pulmonary disease treatment firm Pearl Therapeutics for up to $1.15 billion. One month earlier, it paid $443 million for Omthera Pharmaceuticals, a blood disease researcher.

The Amplimmune transaction is expected to close by the end of the third quarter, pending regulatory approval.

AstraZeneca shares traded 10 cents lower, to $50.58, on Monday afternoon with its market capitalization near $63 billion.

Neither AstraZeneca nor Amplimmune returned calls on Monday.

-- Written by Demitri Diakantonis in New York

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $29.15 0.38%
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs